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Abstract
Background:  Inexpensive antihypertensive drugs are at least as effective and safe as more
expensive drugs. Overuse of newer, more expensive antihypertensive drugs is a poor use of
resources. The potential savings are substantial, but vary across countries, in large part due to
differences in prescribing patterns. We wanted to describe prescribing patterns of antihypertensive
drugs in ten countries and explore possible reasons for inter-country variation.
Methods: National prescribing profiles were determined based on information on sales and
indications for prescribing. We sent a questionnaire to academics and drug regulatory agencies in
Canada, France, Germany, UK, US and the Nordic countries, asking about explanations for
differences in prescribing patterns in their country compared with the other countries. We also
conducted telephone interviews with medical directors of drug companies in the UK and Norway,
the countries with the largest differences in prescribing patterns.
Results: There is considerable variation in prescribing patterns. In the UK thiazides account for
25% of consumption, while the corresponding figure for Norway is 6%. In Norway alpha-blocking
agents account for 8% of consumption, which is more than twice the percentage found in any of
the other countries. Suggested factors to explain inter-country variation included reimbursement
policies, traditions, opinion leaders with conflicts of interests, domestic pharmaceutical production,
and clinical practice guidelines. The medical directors also suggested hypotheses that: Norwegian
physicians are early adopters of new interventions while the British are more conservative; there
are many clinical trials conducted in Norway involving many general practitioners; there is higher
cost-awareness among physicians in the UK, in part due to fund holding; and there are publicly
funded pharmaceutical advisors in the UK.
Conclusion:  Two compelling explanations the variation in prescribing that warrant further
investigation are the promotion of less-expensive drugs by pharmaceutical advisors in UK and the
promotion of more expensive drugs through "seeding trials" in Norway.
Background
In many countries there is a substantial potential for sav-
ings if less expensive drugs, particularly thiazides, are pre-
scribed rather than the more expensive drugs for
hypertension [1]. The potential savings in the UK are £132
million ($200 million) per year (£2.22 ($3.36) per
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inhabitant; figures from the year 2000). The US and Nor-
way could potentially save even more per inhabitant
(£3.21 ($4.86) and £3.55 ($5.38) respectively, year
2000). An important reason for these differences in poten-
tial savings is that thiazides are used more in the UK than
in the US and Norway. In this article we describe and
attempt to explain international variation in prescribing
patterns of antihypertensive drugs.
Methods
We had access to sales figures for anihypertensive drugs
for six countries (Canada, France, Germany, Norway, the
UK and the US) for the year 2000. We also had survey-
based information describing the diagnoses for which the
drugs were being prescribed. This was relevant since anti-
hypertensive drugs are also used for other indications,
such as heart failure (e.g. ACE-inhibitors) and post-myo-
cardial infarction (e.g. beta-blocking agents). The infor-
mation was provided by IMS-Health.
The sales-figures were originally expressed as physical
units (kg), which we transformed to defined daily dos-
ages/1000 inhabitants/day [2]. The defined daily dose
(DDD) is the assumed average dose used for a drug [3].
For each drug-class we estimated the total consumption
by summarizing the consumption for each drug within a
class. The total consumption for each class was then mul-
tiplied with the proportion of prescribing that was done
specifically for hypertension. We estimated the consump-
tion of the various drug classes for each country, and com-
pared them.
The following drug-classes (and ATC-numbers) were
included: alpha blocking agents (C02C A), thiazides
(C03A, C03B og C03E), beta blocking agents (C07), cal-
cium channel blockers (C08), ACE-inhibitors (C09A),
ACE-inhibitors combined with a diuretic (C09B), angi-
otensin II antagonists (C09C), and angiotensin II antago-
nists combined with a diuretic (C09D).
We also obtained official sales statistics for antihyperten-
sive drugs in the Nordic countries (Denmark, Finland, Ice-
land, Norway and Sweden) for 1999, and compared the
patterns of consumption [4]. For these countries we did
not adjust for the proportion of prescribing being made
specifically for hypertension, as we did not have access to
such information.
We circulated those results (figures 1 and 2) to a conven-
ience sample of one academic in each of the included
countries and asked about possible reasons for inter-
country variation in prescribing patterns. The results were
also sent to the drug regulatory agency in each country.
The recipients were asked to answer the following five
questions:
1. Are there specific policies, rules or regulations in place
in your country that may influence the choice of drug in
the treatment of hypertension (e.g. pricing policies, treat-
ment-protocols etc.)?
2. What do you think are the main factors that influence
the choice of drug in the treatment of hypertension in
your country?
3. In particular, why do physicians prescribe newer,
expensive drugs, such as calcium channel blockers or
angiontensin II receptor blockers?
4. Similarly, why do physicians prescribe older, less
expensive drugs, such as thiazides or beta-blockers?
5. We have attached a graph illustrating the profile of sales
of antihypertensive drugs for some countries, including
yours. How would you explain your country's profile in
comparison with the other countries?
Lastly, we contacted the medical directors of the British
and Norwegian affiliates of four major drug companies
with antihypertensive drugs, and conducted a semi-struc-
tured telephone interview exploring possible explanations
for the differences between these two countries, which
had the largest differences in prescribing patterns (See
additional file 1: Interview guide).
Results
Calcium channel blockers and ACE-inhibitors are gener-
ally the most widely used drugs for the treatment of hyper-
tension (figure 1 and Additional file 2: Sales of
antihypertensive drugs, IMS). Apart from that, there is
large variation among the countries with regards to the
use of drugs for the treatment of hypertension.
In the UK thiazides account for 25% of consumption,
while the corresponding figure for Norway is 6%. In Nor-
way alpha-blocking agents account for 8% of consump-
tion, which is more than twice the percentage found in
any of the other countries. The use of combination drugs
in the UK is strikingly low. The prescribing patterns also
vary largely within the Nordic countries (figure 2 and
Additional file 3: Sales of antihypertensive, Nordic
countries).
The overall consumption of antihypertensive drugs is con-
siderably higher in the US than in Canada, France, Nor-
way or the UK (table 1).BMC Health Services Research 2005, 5:21 http://www.biomedcentral.com/1472-6963/5/21
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Possible explanations for inter-country variation
We received answers from researchers in all the ten coun-
tries and drug regulatory agencies in Finland, Norway and
Sweden and from a Department of Health official in the
UK.
There was nearly full consensus among our respondents
that marketing by pharmaceutical companies is the main
explanatory variable for prescribing choices, and particu-
larly the driving force behind the prescribing of newer
drugs, such as calcium channel blockers and angiotensin
II receptor blockers.
There was some variation among the respondents regard-
ing the policies, rules and regulations related to prescrib-
ing of antihypertensive drugs in the various countries, but
few believed that this had a major impact on prescribing.
The exceptions were the Finnish respondents, who
believed that their national clinical guidelines program
could have had an impact, and the UK Department of
Health official who considered central guidance ("espe-
cially NICE guidance") a major factor.
The answers given to our question on why doctors pre-
scribe older drugs was mixed. Some researchers pointed to
price considerations (Denmark, Finland, Canada, US),
and some made statements like "Some physicians pre-
scribe according to evidence-based principles, but they are
probably a minority" (Canada, France). There were
Consumption of drugs for the treatment of hypertension for six countries (percentage distribution within each country) * Figure 1
Consumption of drugs for the treatment of hypertension for six countries (percentage distribution within each 
country) *. *Consumption as defined daily dosages/1000 inhabitants/day. Based on figures on sales (year 2000) and indications 
for prescribing from IMS-Health
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Consumption of antihypertensive drugs within the Nordic countries (percentage distribution within each country)* Figure 2
Consumption of antihypertensive drugs within the Nordic countries (percentage distribution within each 
country)* *Consumption as defined daily dosages/1000 inhabitants/day. Based on official sales statistics from 1999 [4]. No 
adjustment made for the relative proportion of prescribing being done for other indications than the treatment of 
hypertension
Table 1: Consumption of antihypertensive drugs in six countries, based on sales figures provided by IMS-Health (year 2000)
Total consumption of antihypertensives 
(DDDs/1000 inhabitants/day)
Consumption of antihypertensives for 
the treatment of hypertension (DDDs/
1000 inhabitants/day)
Canada 163.6 119.6
France 171.7 133.4
Germany 205.9 145.3
Norway 171.6 115.7
UK 170.6 105.8
US 225.5 165.3
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several possible explanations for the differences in pre-
scribing patterns between their own and the other
countries:
...."it is MOST unusual for UK GPs to use combination
preparations. It is regarded as poor practice." (British
researcher)
"The very low usage of thiazides probably reflects the
views of the prominent specialists and researchers in this
field in Norway" ...... "Many of the experts are deeply
involved in industry sponsored research and tend to
favour new products and their own research." (Norwegian
drug regulator)
"Denmark's relatively large share of thiazides may to
some extent be explained by factors like domestic produc-
tion"...."but may also reflect their better system for contin-
uing drug education among their GPs (e.g. academic
detailing). In Norway this education is almost entirely left
to the pharmaceutical companies." (Norwegian
researcher)
"Beta-blockers have a long tradition in Sweden." (Swedish
researcher)
"I once asked an older cardiologist about the reason for
this difference and the answer was that there was no major
tradition for beta-blockers in Denmark" (Danish
researcher)
"The most striking difference for Canada is the lack of
combination use of thiazides with ACEI and ARBs. This is
probably due to the fact that these combination drugs are
not funded in many of the provinces. This leads to a seem-
ingly greater use of thiazides and ACEIs alone." (Canadian
researcher)
Seven of the eight drug company medical directors
(including two alternates) agreed to be interviewed: four
from Norway and three from the UK.
Differences in physicians' attitudes were thought by all the
directors to partly explain the differences in prescribing
between the UK and Norway; e.g. that British doctors gen-
erally are conservative and slow implementers of new
interventions while Norwegian physicians are "early
adopters":
"My perception is that we Norwegians are, in general,
"early adopters" – we are attracted to the new and "hot",
be it kitchen equipment or other things." (N2)
"UK is in general a conservative country when it comes to
prescribing new drugs. New therapies are slowly taken up"
(UK1)
"I think this [low use of combination drugs] reflects the
general conservatism that is typical of the British." (N2)
"Could be that the British doctors are more conservative –
it wouldn't be surprising knowing how conservative the
British are, in general!" (N4)
"It is, perhaps, true that British doctors comply more with
guidelines than their Norwegian colleagues. The British
are perhaps more respectful towards authorities while the
Norwegians are more individualistic in their attitudes."
(N4)
"It may be true that Norwegian tend to disregard clinical
guidelines and rather adhere to their own convictions.
......It is typically Norwegian that each individual has his
own personal opinion." (N2)
"There is usually a slow uptake of newer drugs in the UK.
New data typically doesn't impact immediately – unless
they're very strong." (UK2)
"One new trial result is not enough for a UK-doctor –
again a consequence of the conservatism we have." (UK3)
The Norwegian directors also believed that conducting tri-
als in general practice has an impact on prescribing and
that a substantially higher number of physicians involved
in such trials in Norway could explain differences in pre-
scribing patterns:
"Many trials are being run in Norway."..... "I believe that
the hand-on experience doctors get from participating in
the trials increases their awareness and influences prac-
tice." (N1)
"I do believe that running a study like this is, by itself, of
value from the marketing perspective." (N2)
"Of course we conduct clinical trials with the aim of devel-
oping newer and better drugs, but a marketing effect is
unavoidable, and is an added benefit for the company."
(N2)
"Yes, involvement by doctors in the running of clinical tri-
als probably has an impact. In Norway a much higher pro-
portion of GPs participate in trials compared to, for
instance, the UK." (N2)
"I don't think that is true [that the differences can be
explained by the higher number of trials that areBMC Health Services Research 2005, 5:21 http://www.biomedcentral.com/1472-6963/5/21
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conducted in Norway]. I can only speak for our company,
but we have run several trials in UK general practice –
often in collaboration with sites in Norway and the other
Scandinavian countries. So this does not fit with my
understanding." (UK1)
"Norwegian physicians are in general rapid implementers
of new therapies. A major explanation for this is probably
the high number of large clinical trials that are run in Nor-
way. Relative to our population the number of patients
participating in clinical trials is about the double of what
can be expected compared to other countries." (N3)
"Norway is a key area for clinical drug trials, e.g. studies of
organoprotective effects of antihypertensive drugs. This
has been driving prescribing to the right in the graph [i.e.
towards the more expensive alternatives]. Recently we
have seen a slight increase in the use of ARBs, for the treat-
ment of migraine. Again, an example of high quality trial
results being rapidly taken up in clinical practice." (N3)
"I don't think participating in trials will lead to a change
in prescribing habit for a UK-doctor." ...... "We do [run
clinical trials where GPs participate] ... but maybe we do it
less than in Norway." (UK3)
British doctors were also believed to be more cost-aware,
mainly due to local budgets which include drug expendi-
tures, thus driving prescribing towards less costly
alternatives:
"In the UK they have given budget-responsibility to the
local GPs, which could limit spending on drugs, for
instance." (N1)
"It's probably true that UK physicians are more cost-
aware. One reason may be their tradition of local budgets.
Actually, I think Norwegian doctors have become less
cost-aware now than they were before. At least that's the
impression I have from speaking to our representatives –
they tell me that the doctors put very little emphasis on
price." (N2)
"Cost considerations are also part of the picture. It is my
impression that UK doctors are more cost sensitive. This
has to do with the limited drug budgets for each practice,
but I think UK doctors also are happy to prescribe thi-
azides and beta-blockers." (UK1)
"Maybe the British physicians are more cost-aware. I think
Norwegian doctors have regarded the drug-reimburse-
ment system as a bottomless pit. They may be concerned
about the costs for their patients, but not the societal
costs." (N4)
"I have mentioned drug formularies... Also, primary care
trusts have budgets they are responsible for, which
includes spending on drugs." (UK2)
"I don't think that UK GPs are particularly acquisition-
cost aware, but the drugs that are included in their formu-
laries have gone through a process of appraisal where cost-
effectiveness is an important element." (UK2)
"It could be that in Norway you focus more on the patient
in front of you. The UK-system is very cost-conscious."
(UK3)
Local influence from pharmaceutical advisors was also
mentioned as an important force that "pushes the use of
thiazides – for pure cost reasons" (UK3). This "local guid-
ance" was also seen as a reason why "UK-doctors are hard
work for industry to influence" (UK3).
Views on the role of evidence among Norwegian and Brit-
ish physicians were contradictory. On the one hand the
directors seemed to agree that there is a "bias for evidence-
based medicine" (UK1) in the UK, but on the other hand
the Norwegian directors claimed that physicians in Nor-
way are very much focused on trial results and particularly
hard endpoints, e.g. effects on mortality rates:
"Our impression is that the doctors in Norway put great
emphasis on documentation – they look at the evidence.
They want trials with hard end-points." (N1)
"I think there is a particular focus on large studies with
survival endpoints among Norwegian doctors." (N2)
"I think Norwegian physicians are particularly interested
in research and the results of clinical trials." (N2)
"I do have the impression that Norwegian physicians are
focused on hard endpoints, but if there is any difference
compared to British doctors I don't know." (N4)
"I think guidelines are important in explaining the UK
prescribing pattern and there is a strong bias for evidence-
based medicine. Thiazides and beta-blockers have been
recommended as first line, and doctors have followed this
recommendation." (UK1)
"UK doctors may be more difficult to persuade, perhaps,
with their strong focus on evidence. They demand trials
that have shown the effectiveness of drugs on hard end
points – their clinical usefulness." (UK1)
"Also in the UK some physicians want hard end-points –
especially the physicians in secondary care. Many GPs are
more focused on controlling the blood pressure." (UK2)BMC Health Services Research 2005, 5:21 http://www.biomedcentral.com/1472-6963/5/21
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"Maybe Norway is less evidence-based and more patient-
focused? ..... There is a fundamental belief in endpoints
and outcomes – there is a hang-up on this in the UK."
(UK3)
The British directors agreed that the low use of combina-
tion drugs in the UK was due to therapeutic traditions
largely seeded at medical school. One of them also
believed that "the general push for generic prescribing
plays a role, since the combinations usually are branded
drugs" (UK3).
The high use of alpha-blockers in Norway was considered
to be an artefact by some since current regulation only
allows for the reimbursement of such drugs if they are
used for hypertension, and not for benign prostate
enlargement. However, one of the directors refuted this,
citing a study conducted among general practitioners
where only 5–10% of reimbursed prescriptions for alpha-
blockers were made for individuals without hypertension.
Two Norwegian directors confirmed that the relationship
between specialists and industry might be a factor:
"Conflicts of interest of opinion leaders may be an issue"
...... "Norway has a rather high number of opinion leaders
in the cardiovascular area that have been active in collab-
oration with industry." (N2)
"Their engagement with industry is important for the serv-
ices they provide to their patients, e.g. the chance of
accessing new therapies, more intense follow-up of
patients etc. This is less so in the UK. For this reason indus-
try may find it more difficult to convince physicians in the
UK with their arguments." (N3)
"To get opinion leader endorsement is important. They
rarely go against established guidelines, so they generally
support the use of thiazides. Also the opinion leaders put
great importance on cost-effectiveness, while tolerability
for instance is less emphasised. Regarding their links to
industry I think they are cautious – they have their integ-
rity to maintain." (UK3)
"One difference might by that Norwegian opinion leaders
seem to be somewhat less keen on promoting a specific
drug – they worry about their credibility." (N2)
"In fact, my guess is that marketing in general – also the
use of opinion leaders – is more aggressive in the UK, if
there is any difference at all." (N1)
One Norwegian director mentioned the role of patients:
"In the UK I think the doctor-patient relationship is more
traditional, with the physician deciding for the patient,
while here the patients are more involved in decision-
making; and when given the choice they prefer the 'latest
model"' (N1).
Financial incentives were mentioned by one UK director:
"In the UK there are local prescribing incentive schemes
that reward generic prescribing, reward high use of drugs
in accordance with guidelines, etc. The reward can be
money, which goes to the clinic. The GPs are independent
contractors – running their own business." (UK3)
One director suggested that a higher threshold for initiat-
ing treatment among Norwegian physicians means that a
higher proportion of those who are treated need more
than one drug, and that this influences the overall pre-
scribing pattern.
Discussion
We have based our analysis on a cross-sectional data from
one year. This may represent an incomplete picture of the
prescribing in the ten countries since we are not able to
detect prescribing trends, which may vary across coun-
tries. Another potential weakness of our analysis is that we
have not taken epidemiological differences into account.
For instance, a lower use of ACE-inhibitors in the US may
be appropriate given the high number of Afro-Americans
and the fact that these drugs are less effective in persons of
African origin. Interestingly, however, the use of ACE-
inhibitors in the US is particularly high.
There is considerable variation in prescribing patterns of
antihypertensive drugs among the countries included in
this study. The UK and Norway are at opposite ends of the
spectrum.
The high use of alpha-blockers in countries such as Nor-
way and the US is of concern since evidence in support of
these drugs is particularly weak. The first major compara-
tive trial of alpha blocking agents and other antihyperten-
sives was stopped early due to the high rate of
cardiovascular disease events among those allocated to
the alpha-blocker [5]. Despite this, the sales of alpha-
blockers in Norway have only gone down slightly (from
8.8 DDDs/1000 inhabitants/day in 2000 to 7.8 DDDs/
1000 inhabitants/day in 2003) [3]. In the US the publica-
tion of the trial results appears to have had a greater
impact on physicians' prescribing habits [6].
Not only do Norwegian physicians tend to choose drugs
from the most expensive drug-classes, they also tend to
select the more expensive drugs within a class (table 2).
For example, metoprolol is the most sold beta-blocking
agent in Norway and it is one of the most expensive drugs
within its class [7]. Moreover, metoprolol is available
from several manufacturers, and the most expensiveBMC Health Services Research 2005, 5:21 http://www.biomedcentral.com/1472-6963/5/21
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version (Selo-Zok®) is the most sold [7]. This explains why
beta-blocking agents have a higher average price than
ACE-inhibitors in Norway (table 2), despite the fact that
most beta-blocking agents are much less expensive than
ACE-inhibitors [7].
If Norwegian physicians were to prescribe antihyperten-
sive drugs similarly to Danish physicians, the annual
expenditure would be reduced by £26 million ($US 40
million), which is about 30% of current spending on
these drugs in Norway. Interestingly, it was pointed out 20
years ago that the Norwegian drug expenditures for anti-
hypertensives would be reduced by 36% if Norway were
to adopt a Danish profile [8].
It is widely believed that marketing efforts from the phar-
maceutical industry have a major impact on physicians'
prescribing [9]. Our informants agreed with this, but the
directors we interviewed did not indicate that marketing
strategies differ much from country to country. According
to them companies base their marketing on global strate-
gies that are adapted locally. However, it is possible that
Norwegian physicians interact more frequently with drug
company representatives, for instance, and that this may
explain some of the variation in prescribing behaviour.
We have collected data on the scope of outreach visits by
industry representatives to general practitioners in Nor-
way, but we have not found similar data for any of the
other countries in this study. Thus, no comparison is
possible.
Non-industry pharmaceutical advisors play an active role
in trying to influence prescribing behaviour among UK
primary care physicians. They use strategies such as locally
developed guidelines, feedback on prescribing, and out-
reach visits. A similar system does not exist in Norway and
this may be one important explanatory factor for the
observed differences between the UK and Norway.
Our survey of researchers and drug regulators yielded few
plausible explanations for the variation in prescribing pat-
terns. It is unlikely that practice guidelines alone have had
an important impact [10]. The higher use of thiazides in
Denmark and the higher use of beta-blockers in Sweden
may be related to domestic production of these agents in
the respective countries, and the lack of reimbursement
may help to explain the lower use of combination drugs
in Canada. These explanations are not likely to explain
other differences.
The medical directors from drug companies in Norway
and the UK suggested that fund holding for general prac-
titioners was an important reason for the higher use of thi-
azides in the UK. However, the findings from numerous
evaluations addressing the effect of fund holding on pre-
scribing do not necessarily support this belief [11].
The assertion that Norwegian physicians are less con-
scious about the societal costs of their prescribing com-
pared to their British colleagues is difficult to validate.
Jacoby and colleagues observed in their interviews with 56
general practitioners in the UK that there was considerable
variation concerning the level of cost-consciousness [12].
There seemed to be a consensus among the Norwegian
medical directors that physicians in their country are par-
ticularly focused on research findings, especially trials that
measure effects in terms of hard endpoints. However, this
does not fit with our impressions. For example, in recent
debates over first line antihypertensive drugs metabolic
effects (soft endpoints), not hard end points, have been at
the centre of the debate. Medical directors from the UK
also did not share the impression that British physicians
show less interest in research findings or put less emphasis
on hard endpoints than their Norwegian colleagues.
Statins are another group of drugs for which the national
prescribing patterns vary greatly [13]. In their recent
paper, Walley and colleagues speculated that a major rea-
son why Norway has the highest use of statins in the
region is "the involvement of Norwegian doctors in semi-
nal trials" [13]. However, this does not explain the varia-
tion in consumption of antihypertensive drugs, since
there are essentially no trials that provide evidence against
the use of thiazides or beta-blockers. A better explanation
may be that participation in trials as such, and not neces-
sarily seminal trials, influences prescribing. Pharmaceuti-
cal companies may include marketing considerations
when planning clinical trials, in particular those con-
ducted after drug approval has been granted. Studies con-
ducted after marketing-approval has been granted are
Table 2: Drug-costs for one year's treatment, in Norway (ranked 
according to price)*
Drug cost*
Thiazide $33 (£22)
ACE-inhibitor $150 (£99)
Beta-blocking agent $174 (£115)
Calcium channel blocker $211 (£139)
Alpha blocking agent $269 (£178)
ACE-inhibitor with thiazide $270 (£178)
Angiotensin II antagonist $288 (£190)
Angiotensin II antagonist with thiazide $328 (£216)
*Based on prices to consumer. The costs were calculated by dividing 
total sales of each drug class by consumption (year 2000). It is 
assumed that the average dose used equals the defined daily dose 
(DDD)BMC Health Services Research 2005, 5:21 http://www.biomedcentral.com/1472-6963/5/21
Page 9 of 10
(page number not for citation purposes)
sometimes labelled "seeding trials", as they may be
designed to "seed" the use of a drug among physicians
[14-16]. All the Norwegian directors in our study seemed
to agree that trial-participation influences prescribing.
Despite searches in several databases, we did not find
research data to support or refute this belief. This is sur-
prising considering concerns that have been raised over
the impact of seed trials [15,16]. Norwegian doctors are
typically paid a bulk sum in the order of NOK 5000 –
15000 (£425 – £1275; $800 – $2400) for every patient
they enrol in clinical trials. The hourly fee for doctors par-
ticipating as investigators in clinical trials in Britain is set
at £193.50 ($360), according to an agreement made by
the British Medical Association and the Association of the
British Pharmaceutical Industry. This fee includes all rele-
vant overheads (Richard Tiner, personal
communication).
For trial-participation to be an effective marketing strategy
it is necessary to recruit as many physicians as possible.
Also, a double blind trial is not the best design if the idea
is for the physicians to obtain "provider-experience" with
a specific drug [14]. In fact, many of the recent trials of
antihypertensive drugs have recruited a very large number
of physicians, and a non-blinded design is common.
National registers of ongoing clinical trials, which could
provide data regarding the extent of seed trials and phase
III randomised trials, are generally either non-existent or
not accessible.
We are not aware of data that document that physicians in
Norway have a higher threshold for initiating treatment
than in the UK. The fact that the consumption of drugs for
hypertension is somewhat higher in Norway suggests the
opposite (table 1).
There was a common belief among the medical directors
that UK physicians are more conservative than their Nor-
wegian colleagues, and it was also suggested that this mir-
rors differences in attitudes that exist in general between
the British and Norwegian societies. We have not identi-
fied research findings that support or challenge this
hypothesis. However, Jacoby et al did observe that the
British general practitioners they interviewed "consist-
ently described themselves as cautious and conservative"
[12].
Two additional hypotheses to explain inter-country varia-
tion were suggested during the review process of this
paper: (1) the use of drug-samples and (2) educational
interventions. There is evidence suggesting that both may
be effective in influencing prescribing of drugs [17,18].
However, we do not have information about the relative
use of such interventions in the countries we have studied.
Conclusion
The fourfold contrasts in use of thiazide and alphablock-
ers in Norway versus the UK suggests that relative risks of
potentially inappropriate prescriptions to Norwegian
hypertensive patients are in the vicinity of 4. Two compel-
ling explanations for the observed variation that warrant
further investigation are the promotion of less-expensive
drugs by pharmaceutical advisors in UK and the promo-
tion of more expensive drugs through seeding trials in
Norway.
Competing interests
Both authors are employed by the Norwegian govern-
ment, which has substantial interest in containing the cost
of health care.
Authors' contributions
AF conceived the study, carried out the survey and inter-
views, prepared the first manuscript and contributed to all
other aspects of the study. ADO contributed to the design
of the study, to the interpretation of data, and made criti-
cal revisions to the manuscript.
Additional material
Acknowledgements
We thank all of the individuals who participated in our survey and inter-
views, including: Bjørn Beerman, Neil Brickel, Martin Eccles, Curt D. Furb-
erg, Francois Gueyffier, Sigurdur Helgason, Paul Hjemdahl, Tessa Ing, Tahir 
Khan, Jan Peter Kösters, Henrik Lund, Steinar Madsen, Marjukka Mäkelä, 
Pirkko Paakkari, Atle Skattebøl, Jørund Straand, Heidrun Sturm Karen 
Marie Ulshagen, James M. Wright, and John Young. We also thank Signe 
Flottorp and Morten Aaserud for important contributions, Elisabeth Erik-
Additional File 1
List of questions used in semi-structured telephone interviews with medi-
cal directors, or their alternates, of pharmaceutical companies.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-5-21-S1.doc]
Additional File 2
Sales figures for each drug-class, and proportions of drugs prescribed for 
hypertension, presented country wise (Canada. France, Germany, UK, 
USA, Norway). Based on IMS-data for the year 2000.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-5-21-S2.doc]
Additional File 3
Sales figures for each drug class, presented country-wise (Denmark, Fin-
land, Iceland, Sweden, Norway). Based on official sales statistics for the 
year 1999.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-5-21-S3.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Health Services Research 2005, 5:21 http://www.biomedcentral.com/1472-6963/5/21
Page 10 of 10
(page number not for citation purposes)
sen and Marit Rønning for their assistance with the use of the Norwegian 
Prescription Database, and Peter Stephens from IMS-Health. The Norwe-
gian Health Services Research Centre, where both authors are employed, 
funded the study. Finally, we thank the peer-reviewers, Joel Lexchin and 
Malcolm Maclure, for valuable comments and criticism.
References
1. Fretheim A, Aaserud M, Oxman AD: The potential savings of
using thiazides as the first choice antihypertensive drug:
cost-minimisation analysis. BMC Health Serv Res 2003, 3:18.
2. WHO Collaborating Centre for Drug Statistics Methodology: ATC
index with DDDs 2000 Oslo, WHO Collaborating Centre for Drug
Statistics Methodology; 2000. 
3. Drug Consumption in Norway 1999-2003. Edited by: Rønning
M. Oslo, Norwegian Institute of Public Health; 2004. 
4. Nielsen A: Medicines consumption in the Nordic countries Edited by:
Nielsen J. Copenhagen, Nordisk Medicinalstatistisk Komité;
2001:171-256. 
5. Major cardiovascular events in hypertensive patients rand-
omized to doxazosin vs chlorthalidone: the antihypertensive
and lipid-lowering treatment to prevent heart attack trial
(ALLHAT). JAMA 2000, 283:1967-1975.
6. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma
J: Impact of clinical trial results on national trends in alpha-
blocker prescribing, 1996-2002. JAMA 2004, 291:54-62.
7. Felleskatalogen AS: Felleskatalogen 43rd edition. Oslo, Felleskatalogen
AS; 2001. 
8. Waaler HT, Hjort PF: The consumption of blood pressure low-
ering drugs in the Nordic countries. In Nordic statistics on
Medicines Uppsala/Oslo, The Nordic Council on Medicines;
1983:195-215. 
9. Goodman B: Do drug company promotions influence physi-
cian behavior? West J Med 2001, 174:232-233.
10. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, Grilli
R, Harvey E, Oxman A, O'Brien MA: Changing provider behavior:
an overview of systematic reviews of interventions. Med Care
2001, 39:II2-45.
11. Gosden T, Torgerson DJ: The effect of fundholding on prescrib-
ing and referral costs: a review of the evidence. Health Policy
1997, 40:103-114.
12. Jacoby A, Smith M, Eccles M: A qualitative study to explore influ-
ences on general practitioners' decisions to prescribe new
drugs. Br J Gen Pract 2003, 53:120-125.
13. Walley T, Folino-Gallo P, Schwabe U, van Ganse E: Variations and
increase in use of statins across Europe: data from adminis-
trative databases. BMJ 2004, 328:385-386.
14. Pena E: The Value of Phase IV. PharmaVoice 2003:8-18.
15. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP: Therapeutic-
class wars--drug promotion in a competitive marketplace. N
Engl J Med 1994, 331:1350-1353.
16. Stephens MD: Marketing aspects of company-sponsored post-
marketing surveillance studies. Drug Saf 1993, 8:1-8.
17. Maclure M, Dormuth C, Naumann T, McCormack J, Rangno R,
Whiteside C, Wright JM: Influences of educational interven-
tions and adverse news about calcium-channel blockers on
first-line prescribing of antihypertensive drugs to elderly
people in British Columbia. Lancet 1998, 352:943-948.
18. Boltri JM, Gordon ER, Vogel RL: Effect of antihypertensive sam-
ples on physician prescribing patterns.  Fam Med 2002,
34:729-731.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/5/21/prepub